Abstract
Mood stabilisers are associated with a wide range of clinically significant drug-drug interactions. The glucuronidation of lamotrigine is inhibited by valproate and induced by oral contraceptives, carbamazepine and phenytoin. Lamotrigine induces the glucuronidation of quetiapine. Valproate is an inhibitor of CYP2C9 and glucuronosyltransferase enzymes and increases plasma levels of some benzodiazepines, tricyclic antidepressants and lamotrigine. Valproate’s metabolism is inhibited by aspirin and erythromycin and induced by carbapenem antibiotics. Carbamazepine is involved in innumerable interactions largely because of its potent ability to induce the activity of CYP3A4 and, to a lesser degree, CYP1A2 enzymes. Carbamazepine thus lowers plasma levels of many drugs including many analgesics, antipsychotics, benzodiazepines, antidepressants and antimicrobial agents. The metabolism of carbamazepine is inhibited by diltiazem, verapamil, danazol, isoniazid and ticlodipine. Lithium is largely renally excreted, a process that is inhibited by NSAIDs, thiazide and loop diuretics, ACE inhibitors and some calcium channel blockers. Lithium may give rise to neurotoxicity when combined with antipsychotics or antidepressants.
Keywords
Search Details
We searched PubMed and Embase in January 2015 using the search terms “metabolism”, “pharmacokinetic” and “interaction” with the following drug names: “valproate”, “valproic”, “divalproex”, “lamotrigine”, “carbamazepine” and “lithium”. We also referred official European Medicines Association Summaries of Product Characteristics for all drugs listed (accessed online January 30, 2015). Reference sections for all retrieved papers were scrutinised for further relevant papers.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Rambeck B, Wolf P (1993) Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet 25:433–443
Magdalou J, Herber R, Bidault R et al (1992) In vitro N-glucuronidation of a novel antiepileptic drug, lamotrigine, by human liver microsomes. J Pharmacol Exp Ther 260:1166–1173
Theis JG, Sidhu J, Palmer J et al (2005) Lack of pharmacokinetic interaction between oxcarbazepine and lamotrigine. Neuropsychopharmacology 30:2269–2274
Jann MW, Hon YY, Shamsi SA et al (2006) Lack of pharmacokinetic interaction between lamotrigine and olanzapine in healthy volunteers. Pharmacotherapy 26:627–633
Sidhu J, Job S, Bullman J et al (2006) Pharmacokinetics and tolerability of lamotrigine and olanzapine coadministered to healthy subjects. Br J Clin Pharmacol 61:420–426
Castberg I, Spigset O (2006) Risperidone and lamotrigine: no evidence of a drug interaction. J Clin Psychiatry 67:1159
Christensen J, Sandgaard AP, Sidenius P et al (2012) Lack of interaction between sertraline and lamotrigine in psychiatric patients: a retrospective study. Pharmacopsychiatry 45:119–121
Odishaw J, Chen C (2000) Effects of steady-state bupropion on the pharmacokinetics of lamotrigine in healthy subjects. Pharmacotherapy 20:1448–1453
Schieber FC, Boulton DW, Balch AH et al (2009) A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmacokinetics of lamotrigine in patients with bipolar I disorder. Hum Psychopharmacol 24:145–152
Anderson GD, Yau MK, Gidal BE et al (1996) Bidirectional interaction of valproate and lamotrigine in healthy subjects. Clin Pharmacol Ther 60:145–156
Kanner AM, Frey M (2000) Adding valproate to lamotrigine: a study of their pharmacokinetic interaction. Neurology 55:588–591
Rowland A, Elliot DJ, Williams JA et al (2006) In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metab Dispos 34:1055–1062
Sabers A, Buchholt JM, Uldall P et al (2001) Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res 47:151–154
Sidhu J, Job S, Singh S et al (2006) The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. Br J Clin Pharmacol 61:191–199
Christensen J, Petrenaite V, Atterman J et al (2007) Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial. Epilepsia 48:484–489
Castberg I, Skogvoll E, Spigset O (2007) Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service. J Clin Psychiatry 68:1540–1545
Andersson ML, Bjorkhem-Bergman L, Lindh JD (2011) Possible drug-drug interaction between quetiapine and lamotrigine – evidence from a Swedish TDM database. Br J Clin Pharmacol 72:153–156
Weintraub D, Buchsbaum R, Resor SR Jr et al (2005) Effect of antiepileptic drug comedication on lamotrigine clearance. Arch Neurol 62:1432–1436
Warner T, Patsalos PN, Prevett M et al (1992) Lamotrigine-induced carbamazepine toxicity: an interaction with carbamazepine-10,11-epoxide. Epilepsy Res 11:147–150
Binnie CD, van Emde Boas W, Kasteleijn-Nolste-Trenite DG et al (1986) Acute effects of lamotrigine (BW430C) in persons with epilepsy. Epilepsia 27:248–254
Anderson GD, Gidal BE, Messenheimer JA et al (2002) Time course of lamotrigine de-induction: impact of step-wise withdrawal of carbamazepine or phenytoin. Epilepsy Res 49:211–217
van der Lee MJ, Dawood L, ter Hofstede HJ et al (2006) Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects. Clin Pharmacol Ther 80:159–168
DeVane CL (2003) Pharmacokinetics, drug interactions, and tolerability of valproate. Psychopharmacol Bull 37(Suppl 2):25–42
Gunes A, Bilir E, Zengil H et al (2007) Inhibitory effect of valproic acid on cytochrome P450 2C9 activity in epilepsy patients. Basic Clin Pharmacol Toxicol 100:383–386
Sandson NB, Marcucci C, Bourke DL et al (2006) An interaction between aspirin and valproate: the relevance of plasma protein displacement drug-drug interactions. Am J Psychiatry 163:1891–1896
Abbott FS, Kassam J, Orr JM et al (1986) The effect of aspirin on valproic acid metabolism. Clin Pharmacol Ther 40:94–100
Levy RH (1984) Variability in level-dose ratio of valproate: monotherapy versus polytherapy. Epilepsia 25(Suppl 1):S10–S13
Chang SL, Levy RH (1985) Inhibition of epoxidation of carbamazepine by valproic acid in the isolated perfused rat liver. J Pharmacokinet Biopharm 13:453–466
Pisani F, Caputo M, Fazio A et al (1990) Interaction of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine, with valproate: a pharmacokinetic study. Epilepsia 31:339–342
McKee PJ, Blacklaw J, Butler E et al (1992) Variability and clinical relevance of the interaction between sodium valproate and carbamazepine in epileptic patients. Epilepsy Res 11:193–198
Bernus I, Dickinson RG, Hooper WD et al (1997) The mechanism of the carbamazepine-valproate interaction in humans. Br J Clin Pharmacol 44:21–27
Mattson GF, Mattson RH, Cramer JA (1982) Interaction between valproic acid and carbamazepine: an in vitro study of protein binding. Ther Drug Monit 4:181–184
Panesar SK, Orr JM, Farrell K et al (1989) The effect of carbamazepine on valproic acid disposition in adult volunteers. Br J Clin Pharmacol 27:323–328
Winter HR, Devane CL, Figueroa C et al (2007) Open-label steady-state pharmacokinetic drug interaction study on co-administered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder. Hum Psychopharmacol 22:469–476
Huang CC, Wei IH (2010) Unexpected interaction between quetiapine and valproate in patients with bipolar disorder. Gen Hosp Psychiatry 32:446.e1–2
Halaby A, Haddad R, Naja WJ (2013) Hyperammonemia induced by interaction of valproate and quetiapine. Curr Drug Saf 8:284–286
Anderson GD, Gidal BE, Kantor ED et al (1994) Lorazepam-valproate interaction: studies in normal subjects and isolated perfused rat liver. Epilepsia 35:221–225
Watson WA (1979) Interaction between clonazepam and sodium valproate. N Engl J Med 300:678–679
Browne TR (1979) Reply to Watson WA – interaction between clonazepam and sodium valproate. N Engl J Med 300:679
Vandel S, Bertschy G, Jounet JM et al (1988) Valpromide increases the plasma concentrations of amitriptyline and its metabolite nortriptyline in depressive patients. Ther Drug Monit 10:386–389
Fu C, Katzman M, Goldbloom DS (1994) Valproate/nortriptyline interaction. J Clin Psychopharmacol 14:205–206
Fehr C, Grunder G, Hiemke C et al (2000) Increase in serum clomipramine concentrations caused by valproate. J Clin Psychopharmacol 20:493–494
DeToledo JC, Haddad H, Ramsay RE (1997) Status epilepticus associated with the combination of valproic acid and clomipramine. Ther Drug Monit 19:71–73
Bertschy G, Vandel S, Jounet JM et al (1990) Valpromide-amitriptyline interaction. Increase in the bioavailability of amitriptyline and nortriptyline caused by valpromide. Encéphale 16:43–45
Nagai K, Shimizu T, Togo A et al (1997) Decrease in serum levels of valproic acid during treatment with a new carbapenem, panipenem/betamipron. J Antimicrob Chemother 39:295–296
Muzyk AJ, Candeloro CL, Christopher EJ (2010) Drug interaction between carbapenems and extended-release divalproex sodium in a patient with schizoaffective disorder. Gen Hosp Psychiatry 32:560.e1–3
Taha FA, Hammond DN, Sheth RD (2013) Seizures from valproate-carbapenem interaction. Pediatr Neurol 49:279–281
Spriet I, Goyens J, Meersseman W et al (2007) Interaction between valproate and meropenem: a retrospective study. Ann Pharmacother 41:1130–1136
Omoda K, Murakami T, Yumoto R et al (2005) Increased erythrocyte distribution of valproic acid in pharmacokinetic interaction with carbapenem antibiotics in rat and human. J Pharm Sci 94:1685–1693
Costello LE, Suppes T (1995) A clinically significant interaction between clozapine and valproate. J Clin Psychopharmacol 15:139–141
Taylor D (1997) Pharmacokinetic interactions involving clozapine. Br J Psychiatry 171:109–112
Redington K, Wells C, Petito F (1992) Erythromycin and valproate interaction. Ann Intern Med 116:877–878
Bergemann N, Kress KR, Bu-Tair F et al (2006) Valproate lowers plasma concentration of olanzapine. J Clin Psychopharmacol 26:432–434
Jonville AP, Gauchez AS, Autret E et al (1991) Interaction between isoniazid and valproate: a case of valproate overdosage. Eur J Clin Pharmacol 40:197–198
Kapetanovic IM, Kupferberg HJ, Porter RJ et al (1981) Mechanism of valproate-phenobarbital interaction in epileptic patients. Clin Pharmacol Ther 29:480–486
Annapandian VM, John GT, Mathew BS et al (2009) Pharmacokinetic interaction between sodium valproate and mycophenolate in renal allograft recipients. Transplantation 88:1143–1145
Spina E, Pisani F, Perucca E (1996) Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. Clin Pharmacokinet 31:198–214
Dresser GK, Spence JD, Bailey DG (2000) Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38:41–57
Tempelhoff R, Modica PA, Spitznagel EL Jr (1990) Anticonvulsant therapy increases fentanyl requirements during anaesthesia for craniotomy. Can J Anaesth 37:327–332
Kuhn KL, Halikas JA, Kemp KD (1989) Carbamazepine treatment of cocaine dependence in methadone maintenance patients with dual opiate-cocaine addiction. NIDA Res Monogr 95:316–317
Dam M, Christiansen J (1977) Interaction of propoxyphene with carbamazepine. Lancet 2:509
Wroblewski BA, Singer WD, Whyte J (1986) Carbamazepine-erythromycin interaction. Case studies and clinical significance. JAMA 255:1165–1167
O’Connor NK, Fris J (1994) Clarithromycin-carbamazepine interaction in a clinical setting. J Am Board Fam Pract 7:489–492
Albani F, Riva R, Baruzzi A (1993) Clarithromycin-carbamazepine interaction: a case report. Epilepsia 34:161–162
Herman D, Locatelli I, Grabnar I et al (2006) The influence of co-treatment with carbamazepine, amiodarone and statins on warfarin metabolism and maintenance dose. Eur J Clin Pharmacol 62:291–296
Ross JR, Beeley L (1980) Interaction between carbamazepine and warfarin. Br Med J 280:1415–1416
Kendall AG, Boivin M (1981) Warfarin-carbamazepine interaction. Ann Intern Med 94:280
Jerling M, Bertilsson L, Sjoqvist F (1994) The use of therapeutic drug monitoring data to document kinetic drug interactions: an example with amitriptyline and nortriptyline. Ther Drug Monit 16:1–12
Szymura-Oleksiak J, Wyska E, Wasieczko A (2001) Pharmacokinetic interaction between imipramine and carbamazepine in patients with major depression. Psychopharmacology (Berl) 154:38–42
Sitsen J, Maris F, Timmer C (2001) Drug-drug interaction studies with mirtazapine and carbamazepine in healthy male subjects. Eur J Drug Metab Pharmacokinet 26:109–121
Rakic Ignjatovic A, Miljkovic B, Todorovic D et al (2009) Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study. Br J Clin Pharmacol 67:199–208
Khan A, Shad MU, Preskorn SH (2000) Lack of sertraline efficacy probably due to an interaction with carbamazepine. J Clin Psychiatry 61:526–527
Martinelli V, Bocchetta A, Palmas AM et al (1993) An interaction between carbamazepine and fluvoxamine. Br J Clin Pharmacol 36:615–616
Sanchez-Romero A, Mayordomo-Aranda A, Garcia-Delgado R et al (2011) Probable interaction between trazodone and carbamazepine. Pharmacopsychiatry 44:158–159
Romero AS, Delgado RG, Pena MF (1999) Interaction between trazodone and carbamazepine. Ann Pharmacother 33:1370
Sisodiya SM, Sander JW, Patsalos PN (2002) Carbamazepine toxicity during combination therapy with levetiracetam: a pharmacodynamic interaction. Epilepsy Res 48:217–219
Sennoune S, Iliadis A, Bonneton J et al (1996) Steady state pharmacokinetics of carbamazepine-phenobarbital interaction in patients with epilepsy. Biopharm Drug Dispos 17:155–164
Mack CJ, Kuc S, Mulcrone SA et al (2002) Interaction of topiramate with carbamazepine: two case reports and a review of clinical experience. Seizure 11:464–467
Iwahashi K, Miyatake R, Suwaki H et al (1995) The drug-drug interaction effects of haloperidol on plasma carbamazepine levels. Clin Neuropharmacol 18:233–236
Collins DM, Gidal BE, Pitterle ME (1993) Potential interaction between carbamazepine and loxapine: case report and retrospective review. Ann Pharmacother 27:1180–1187
Lucas RA, Gilfillan DJ, Bergstrom RF (1998) A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism. Eur J Clin Pharmacol 54:639–643
Yasui-Furukori N, Kubo K, Ishioka M et al (2013) Interaction between paliperidone and carbamazepine. Ther Drug Monit 35:649–652
Nickl-Jockschat T, Paulzen M, Schneider F et al (2009) Drug interaction can lead to undetectable serum concentrations of quetiapine in the presence of carbamazepine. Clin Neuropharmacol 32:55
Ono S, Mihara K, Suzuki A et al (2002) Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes. Psychopharmacology (Berl) 162:50–54
Ji P, Damle B, Xie J et al (2008) Pharmacokinetic interaction between efavirenz and carbamazepine after multiple-dose administration in healthy subjects. J Clin Pharmacol 48:948–956
Hugen PW, Burger DM, Brinkman K et al (2000) Carbamazepine – indinavir interaction causes antiretroviral therapy failure. Ann Pharmacother 34:465–470
Furukori H, Otani K, Yasui N et al (1998) Effect of carbamazepine on the single oral dose pharmacokinetics of alprazolam. Neuropsychopharmacology 18:364–369
Levy RH, Lane EA, Guyot M et al (1983) Analysis of parent drug-metabolite relationship in the presence of an inducer. Application to the carbamazepine-clobazam interaction in normal man. Drug Metab Dispos 11:286–292
Yukawa E, Satou M, Nonaka T et al (2002) Pharmacoepidemiologic investigation of clonazepam relative clearance by mixed-effect modeling using routine clinical pharmacokinetic data in Japanese patients. J Clin Pharmacol 42:81–88
Backman JT, Olkkola KT, Ojala M et al (1996) Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. Epilepsia 37:253–257
Ahmad S (1990) Diltiazem-carbamazepine interaction. Am Heart J 120:1485–1486
Brodie MJ, MacPhee GJ (1986) Carbamazepine neurotoxicity precipitated by diltiazem. Br Med J (Clin Res Ed) 292:1170–1171
Soto Alvarez J, Sacristan Del Castillo JA, Alsar Ortiz MJ (1991) Effect of carbamazepine on cyclosporin blood level. Nephron 58:235–236
Kramer G, Theisohn M, von Unruh GE et al (1986) Carbamazepine-danazol drug interaction: its mechanism examined by a stable isotope technique. Ther Drug Monit 8:387–392
Zielinski JJ, Lichten EM, Haidukewych D (1987) Clinically significant danazol-carbamazepine interaction. Ther Drug Monit 9:24–27
Tsouli S, Maranis S, Kyritsis AP (2011) Fluconazole-carbamazepine interaction in a patient with bipolar disorder. Psychiatry Clin Neurosci 65:112
Block SH (1982) Carbamazepine-isoniazid interaction. Pediatrics 69:494–495
Wright JM (1983) Carbamazepine-isoniazid interaction. Pediatrics 71:139
Marsden JR (1988) Effect of isotretinoin on carbamazepine pharmacokinetics. Br J Dermatol 119:403–404
Vlase L, Neag M, Popa A et al (2011) Pharmacokinetic interaction between ivabradine and carbamazepine in healthy volunteers. J Clin Pharm Ther 36:225–229
Spacek A, Neiger FX, Krenn CG et al (1999) Rocuronium-induced neuromuscular block is affected by chronic carbamazepine therapy. Anesthesiology 90:109–112
Davis AR, Westhoff CL, Stanczyk FZ (2011) Carbamazepine coadministration with an oral contraceptive: effects on steroid pharmacokinetics, ovulation, and bleeding. Epilepsia 52:243–247
Olivesi A (1986) Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. Biomed Pharmacother 40:301–308
Wada K, Takada M, Sakai M et al (2009) Drug interaction between tacrolimus and carbamazepine in a Japanese heart transplant recipient: a case report. J Heart Lung Transplant 28:409–411
Rosenberry KR, Defusco CJ, Mansmann HC Jr et al (1983) Reduced theophylline half-life induced by carbamazepine therapy. J Pediatr 102:472–474
Mitchell EA, Dower JC, Green RJ (1986) Interaction between carbamazepine and theophylline. N Z Med J 99:69–70
Brown RI, Cooper TG (1997) Ticlopidine-carbamazepine interaction in a coronary stent patient. Can J Cardiol 13:853–854
Vlase L, Popa A, Neag M et al (2011) Pharmacokinetic interaction between zolpidem and carbamazepine in healthy volunteers. J Clin Pharmacol 51:1233–1236
British Medical Association and Royal Pharmaceutical Society of Great Britain (2014) British national formulary, 68th edn. BMJ Group and Pharmaceutical Press, London
Malhi GS, Tanious M (2011) Optimal frequency of lithium administration in the treatment of bipolar disorder: clinical and dosing considerations. CNS Drugs 25:289–298
Ward ME, Musa MN, Bailey L (1994) Clinical pharmacokinetics of lithium. J Clin Pharmacol 34:280–285
Price LH, Heninger GR (1994) Lithium in the treatment of mood disorders. N Engl J Med 331:591–598
Keitner GI, Rahman S (1984) Reversible neurotoxicity with combined lithium-haloperidol administration. J Clin Psychopharmacol 4:104–105
Sandyk R, Hurwitz MD (1983) Toxic irreversible encephalopathy induced by lithium carbonate and haloperidol. A report of 2 cases. S Afr Med J 64:875–876
Cohen WJ, Cohen NH (1974) Lithium carbonate, haloperidol, and irreversible brain damage. JAMA 230:1283–1287
Coffey CE, Ross DR (1980) Treatment of lithium/neuroleptic neurotoxicity during lithium maintenance. Am J Psychiatry 137:736–737
Tharoor H, Deora S, Chauhan A et al (2007) Lithium-neuroleptic combination leading to permanent neurological sequelae. German J Psychiatry 10:18–20
Goldney RD, Spence ND (1986) Safety of the combination of lithium and neuroleptic drugs. Am J Psychiatry 143:882–884
Prakash R, Kelwala S, Ban TA (1982) Neurotoxicity with combined administration of lithium and a neuroleptic. Compr Psychiatry 23:567–571
Bailine SH, Doft M (1986) Neurotoxicity induced by combined lithium-thioridazine treatment. Biol Psychiatry 21:834–837
Swanson CL Jr, Price WA, McEvoy JP (1995) Effects of concomitant risperidone and lithium treatment. Am J Psychiatry 152:1096
Swartz CM (2001) Olanzapine-lithium encephalopathy. Psychosomatics 42:370
Bergemann N, Bu-Tair F, Kress KR et al (2007) Increase in plasma concentration of amisulpride after addition of concomitant lithium. J Clin Psychopharmacol 27:546–549
Rivera-Calimlim L, Kerzner B, Karch FE (1978) Effect of lithium on plasma chlorpromazine levels. Clin Pharmacol Ther 23:451–455
Garcia G, Crismon ML, Dorson PG (1994) Seizures in two patients after the addition of lithium to a clozapine regimen. J Clin Psychopharmacol 14:426–428
Kanaan RA, Kerwin RW (2006) Lithium and clozapine rechallenge: a restrospective case analysis. J Clin Psychiatry 67:756–760
Finley PR, Warner MD, Peabody CA (1995) Clinical relevance of drug interactions with lithium. Clin Pharmacokinet 29:172–191
Petersen V, Hvidt S, Thomsen K et al (1974) Effect of prolonged thiazide treatment on renal lithium clearance. Br Med J 3:143–145
Poust RI, Mallinger AG, Mallinger J et al (1976) Effect of chlorothiazide on the pharmacokinetics of lithium in plasma and erythrocytes. Psychopharmacol Commun 2:273–284
Helms PM (1982) Lithium-hydrochlorothiazide interaction? Am J Psychiatry 139:1082
Davies DL, Wilson GM (1975) Diuretics: mechanism of action and clinical application. Drugs 9:178–226
Amdisen A (1982) Lithium and drug interactions. Drugs 24:133–139
Pharmaceutical Press (2015) Stockley’s drug interactions. https://www.medicinescomplete.com/
Himmelhoch JM, Forrest J, Neil JF et al (1977) Thiazide-lithium synergy in refractory mood swings. Am J Psychiatry 134:149–152
Himmelhoch JM, Poust RI, Mallinger AG et al (1977) Adjustment of lithium dose during lithium-chlorothiazide therapy. Clin Pharmacol Ther 22:225–227
Jefferson JW, Kalin NH (1979) Serum lithium levels and long-term diuretic use. JAMA 241:1134–1136
Juurlink DN, Mamdani MM, Kopp A et al (2004) Drug-induced lithium toxicity in the elderly: a population-based study. J Am Geriatr Soc 52:794–798
Crabtree BL, Mack JE, Johnson CD et al (1991) Comparison of the effects of hydrochlorothiazide and furosemide on lithium disposition. Am J Psychiatry 148:1060–1063
Kosten TR, Forrest JN (1986) Treatment of severe lithium-induced polyuria with amiloride. Am J Psychiatry 143:1563–1568
Batlle DC, von Riotte AB, Gaviria M et al (1985) Amelioration of polyuria by amiloride in patients receiving long-term lithium therapy. N Engl J Med 312:408–414
Wetzels JF, van Bergeijk JD, Hoitsma AJ et al (1989) Triamterene increases lithium excretion in healthy subjects: evidence for lithium transport in the cortical collecting tubule. Nephrol Dial Transplant 4:939–942
Baer L, Platman SR, Kassir S et al (1971) Mechanisms of renal lithium handling and their relationship to mineralocorticoids: a dissociation between sodium and lithium ions. J Psychiatr Res 8:91–105
Thomsen K, Schou M (1968) Renal lithium excretion in man. Am J Physiol 215:823–827
Pyevich D, Bogenschutz MP (2001) Herbal diuretics and lithium toxicity. Am J Psychiatry 158:1329
Correa FJ, Eiser AR (1992) Angiotensin-converting enzyme inhibitors and lithium toxicity. Am J Med 93:108–109
Douste-Blazy P, Rostin M, Livarek B et al (1986) Angiotensin converting enzyme inhibitors and lithium treatment. Lancet 1:1448
Finley PR, O’Brien JG, Coleman RW (1996) Lithium and angiotensin-converting enzyme inhibitors: evaluation of a potential interaction. J Clin Psychopharmacol 16:68–71
Lehmann K, Ritz E (1995) Angiotensin-converting enzyme inhibitors may cause renal dysfunction in patients on long-term lithium treatment. Am J Kidney Dis 25:82–87
Leung M, Remick RA (2000) Potential drug interaction between lithium and valsartan. J Clin Psychopharmacol 20:392–393
Blanche P, Raynaud E, Kerob D et al (1997) Lithium intoxication in an elderly patient after combined treatment with losartan. Eur J Clin Pharmacol 52:501
Phelan KM, Mosholder AD, Lu S (2003) Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs. J Clin Psychiatry 64:1328–1334
Frolich JC, Leftwich R, Ragheb M et al (1979) Indomethacin increases plasma lithium. Br Med J 1:1115–1116
Reimann IW, Diener U, Frolich JC (1983) Indomethacin but not aspirin increases plasma lithium ion levels. Arch Gen Psychiatry 40:283–286
Monji A, Maekawa T, Miura T et al (2002) Interactions between lithium and non-steroidal antiinflammatory drugs. Clin Neuropharmacol 25:241–242
Jones MT, Stoner SC (2000) Increased lithium concentrations reported in patients treated with sulindac. J Clin Psychiatry 61:527–528
Furnell MM, Davies J (1985) The effect of sulindac on lithium therapy. Drug Intell Clin Pharm 19:374–376
Ragheb M, Powell AL (1986) Lithium interaction with sulindac and naproxen. J Clin Psychopharmacol 6:150–154
Ragheb MA, Powell AL (1986) Failure of sulindac to increase serum lithium levels. J Clin Psychiatry 47:33–34
Taylor D, Paton C, Kapur S (2015) Maudsley prescribing guidelines in psychiatry, 12th edn. Wiley Blackwell, Oxford/London
Wright BA, Jarrett DB (1991) Lithium and calcium channel blockers: possible neurotoxicity. Biol Psychiatry 30:635–636
Dubovsky SL, Franks RD, Allen S (1987) Verapamil: a new antimanic drug with potential interactions with lithium. J Clin Psychiatry 48:371–372
Bruun NE, Ibsen H, Skott P et al (1988) Lithium clearance and renal tubular sodium handling during acute and long-term nifedipine treatment in essential hypertension. Clin Sci (Lond) 75:609–613
Dubovsky SL, Christiano J, Daniell LC et al (1989) Increased platelet intracellular calcium concentration in patients with bipolar affective disorders. Arch Gen Psychiatry 46:632–638
Pazzaglia PJ, Post RM, Ketter TA et al (1993) Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation. Psychiatry Res 49:257–272
Mallinger AG, Thase ME, Haskett R et al (2008) Verapamil augmentation of lithium treatment improves outcome in mania unresponsive to lithium alone: preliminary findings and a discussion of therapeutic mechanisms. Bipolar Disord 10:856–866
Spina E, Perucca E (2002) Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. Epilepsia 43(Suppl 2):37–44
Mayan H, Golubev N, Dinour D et al (2001) Lithium intoxication due to carbamazepine-induced renal failure. Ann Pharmacother 35:560–562
Novartis Pharmaceuticals UK Limited (2014) Summary of product characteristics. Tegretol tablets 100mg, 200mg, 400mg. https://www.medicines.org.uk/emc/medicine/1328
Perry PJ, Calloway RA, Cook BL et al (1984) Theophylline precipitated alterations of lithium clearance. Acta Psychiatr Scand 69:528–537
Evans M, Marwick P (1990) Fluvoxamine and lithium: an unusual interaction. Br J Psychiatry 156:286
Sobanski T, Bagli M, Laux G et al (1997) Serotonin syndrome after lithium add-on medication to paroxetine. Pharmacopsychiatry 30:106–107
Adan-Manes J, Novalbos J, Lopez-Rodriguez R et al (2006) Lithium and venlafaxine interaction: a case of serotonin syndrome. J Clin Pharm Ther 31:397–400
Fava S, Galizia AC (1995) Neuroleptic malignant syndrome and lithium carbonate. J Psychiatry Neurosci 20:305–306
Kojima H, Terao T, Yoshimura R (1993) Serotonin syndrome during clomipramine and lithium treatment. Am J Psychiatry 150:1897
Demers RG, Heninger GR (1971) Sodium intake and lithium treatment in mania. Am J Psychiatry 128:100–104
Sanofi (2014) Summary of product characteristics. Priadel 400mg prolonged release tablets. https://www.medicines.org.uk/
Yassa R (1986) Lithium-methyldopa interaction. CMAJ 134:141–142
Osanloo E, Deglin JH (1980) Interaction of lithium and methyldopa. Ann Intern Med 92:433–434
Actavis UK Ltd (2012) Summary of product characteristics. Methyldopa tablets BP 500mg. https://www.medicines.org.uk/
Ayd FJ Jr (1982) Metronidazole-induced lithium intoxication. Int Drug Ther Newsl 17:15–16
Teicher MH, Altesman RI, Cole JO et al (1987) Possible nephrotoxic interaction of lithium and metronidazole. JAMA 257:3365–3366
McGennis AJ (1978) Lithium carbonate and tetracycline interaction. Br Med J 1:1183
Borden H, Clarke MT, Katz H (1974) The use of pancuronium bromide in patients receiving lithium carbonate. Can Anaesth Soc J 21:79–82
Hill GE, Wong KC, Hodges MR (1976) Potentiation of succinylcholine neuromuscular blockade by lithium carbonate. Anesthesiology 44:439–442
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Taylor, D., Vallianatou, K. (2016). Clinically Significant Interactions with Mood Stabilisers. In: Jann, M., Penzak, S., Cohen, L. (eds) Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents. Adis, Cham. https://doi.org/10.1007/978-3-319-27883-4_17
Download citation
DOI: https://doi.org/10.1007/978-3-319-27883-4_17
Published:
Publisher Name: Adis, Cham
Print ISBN: 978-3-319-27881-0
Online ISBN: 978-3-319-27883-4
eBook Packages: MedicineMedicine (R0)